StockData
Genmab A/S logo

Genmab A/S (GMAB) company profile

GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Score 0/30
$51.96+0.39 (+0.76%)

Close on Nov 17, 2026

About Genmab A/S

Pharmaceutical Preparations, SIC 2834

Genmab A/S is a biotechnology company focused on developing antibody-based therapeutics for the treatment of diseases, primarily targeting cancer indications such as multiple myeloma. The company creates proprietary antibody technologies and therapies while also collaborating with pharmaceutical partners to develop, acquire, and commercialize products, including daratumumab and investigational candidates like petosemtamab and Rina-S. Its treatments are designed for healthcare systems, physicians, and patient populations requiring specialized therapies, including patients who have failed prior therapies.

Headquartered in Valby within the municipality of Copenhagen, Denmark, the company conducts its operations internationally, with clinical trials and commercial distribution spanning regions including the United States, Europe, and Japan. The company operates research and clinical programs encompassing multiple phase II and phase III clinical studies across targeted territories.

Summary of the business section of Genmab A/S's latest annual report, written by StockData.

Company profile

Company

Legal name
Genmab A/S
Headquarters
1253 Copenhagen K, G7
Address
Toldbodgade 33 00000
Website
genmab.com
Employees
3,029, Dec 31, 2025
Industry
Pharmaceutical Preparations
Auditor
Deloitte, Copenhagen

Stock & identifiers

Ticker
GMAB
Other tickers
GNMSF
Exchange
Nasdaq
IPO date
Jul 19, 2019
Shares outstanding
129M, Dec 31, 2025
Filer category
Large accelerated filer
Stock splits
5-for-1, May 1, 2018
SEC CIK
1434265
CUSIP
372303206
ISIN
US3723032062
FIGI
BBG004MPKM64
Share class FIGI
BBG004MPKMY3
LEI
529900MTJPDPE4MHJ122
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

No recent ownership filings by officers or directors

Genmab A/S's leadership is listed in its proxy statement (Form DEF 14A).

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 19, 2019
Offer price
$17.75
Securities offered
28,500,000
Gross proceeds
$505.88M
Exchange
Nasdaq
Lock-up ends (est.)
Jan 15, 2020

“We are selling 28,500,000 ADSs at an initial public offering price of $17.75 per ADS.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025 , we had 3,029 employees; 556 in Denmark, 946 in the Netherlands, 1,158 in the US, 220 in”

Corporate history

Events identified from SEC filings

See a number that looks wrong?